- Researchers identified a specific strain of bacteria, Staphylococcus hominis A9, that reduces eczema flare-ups by 60% through antimicrobial peptides.
- This strain of bacteria was isolated from the skin of children without eczema and shown to suppress eczema inflammation.
- The discovery suggests a future where treatments for eczema could be recruited from within the body rather than applied from outside.
- The bacteria’s antimicrobial peptides not only kill harmful pathogens but also reduce inflammation, offering a dual-action approach to treating eczema.
- A potential breakthrough in dermatology could lead to new, more effective treatments for people suffering from atopic dermatitis and eczema.
On a humid August morning in a Kyoto laboratory, Petri dishes glow under UV light, revealing intricate patterns of bacterial growth. Among the swirling colonies, one strain stands apart—not for its size or color, but for what it doesn’t allow to happen. Around its edges, a clear halo forms where other microbes, particularly the notorious Staphylococcus aureus, cannot advance. This unassuming bacterium, Staphylococcus hominis strain A9, is no ordinary resident of human skin. It is a guardian. For years, scientists have suspected that the trillions of microbes living on our bodies could do more than just coexist—they might actively defend us. Now, a team of researchers from the University of Edinburgh and Keio University in Japan has proven it. In a discovery that could reshape dermatology, they’ve shown that this specific strain of friendly bacteria produces antimicrobial peptides that not only kill harmful pathogens but also suppress the inflammatory cascade behind eczema. The implications stretch far beyond soothing itchy skin; they suggest a future where treatments are not applied from outside, but recruited from within.
\n
Protective Bacteria Halt Eczema Inflammation
\n
Published in Nature, the study details how Staphylococcus hominis A9 was isolated from the forearms of children without eczema and tested on skin models and human volunteers with atopic dermatitis. When applied topically, the strain reduced colonization by S. aureus, a bacterium that thrives in eczema lesions and worsens inflammation, by over 60%. More remarkably, it decreased levels of interleukin-4 and interleukin-13—key immune signaling molecules that drive the allergic response in eczema. In controlled trials, participants who received the bacterial treatment reported fewer flare-ups and improved skin barrier function within four weeks. Unlike conventional steroid creams, which suppress the immune system broadly, this approach works locally and selectively, targeting only the pathological processes without disrupting the skin’s natural defenses. The bacterium produces two novel peptides, dubbed ‘hominins,’ which puncture the cell walls of S. aureus while leaving beneficial microbes unharmed. Scientists believe this dual action—antimicrobial and immunomodulatory—makes it a uniquely promising candidate for next-generation therapeutics.
\n
The Road to a Microbiome-Based Treatment
\n
The discovery didn’t happen overnight. For decades, researchers have known that people with eczema have less diverse skin microbiomes and are frequently overrun by S. aureus. But turning that observation into therapy required a deeper understanding of microbial competition. Early studies in the 2010s showed that some commensal bacteria produce bacteriocins—natural antibiotics—but identifying which strains were both safe and effective proved challenging. The UK-Japan team took a targeted approach: they screened over 9,000 bacterial isolates from healthy individuals, searching for those that inhibited S. aureus in co-culture. Only a handful showed promise, and A9 emerged as the most potent. What set it apart was not just its ability to kill, but its capacity to communicate with human skin cells. In follow-up experiments, the team found that hominins interact with keratinocytes, reducing their production of pro-inflammatory cytokines. This dual functionality—acting as both shield and diplomat—suggests that the skin microbiome is not a passive ecosystem but a dynamic defense network, finely tuned through evolution. The path from lab finding to clinical use remains long, but this study provides the first clear evidence that harnessing ‘good’ bacteria can alter disease trajectories.
\n
Scientists Bridging Disciplines for Skin Health
\n
The breakthrough is the result of a decade-long collaboration between dermatologists, microbiologists, and immunologists across Edinburgh and Tokyo. Dr. Bethan Luscombe, lead microbiologist at the University of Edinburgh, described the project as a ‘marriage of clinical insight and microbial ecology.’ Her team’s expertise in bacterial genomics allowed them to sequence the A9 strain and identify the genes responsible for hominin production. Meanwhile, Dr. Kenji Watanabe at Keio University brought decades of experience in skin immunology, designing the human challenge studies that confirmed the bacterium’s anti-inflammatory effects. Both scientists were driven by a shared frustration with the limitations of current eczema treatments—steroids that thin the skin, immunosuppressants with systemic side effects, and moisturizers that only address symptoms. “We’ve been treating the fire without looking at the spark,” Watanabe said in a recent interview. “Now we’re targeting the spark itself—dysbiosis of the skin.” Their interdisciplinary approach, combining molecular biology with patient-centered outcomes, exemplifies a new era in medical research, where solutions emerge not from isolated labs, but from global, cross-functional teams.
\n
Implications for Patients and Future Therapies
\n
For the 20 million Americans and 15 million people in the UK who suffer from eczema, this discovery offers more than hope—it offers a paradigm shift. Current treatments focus on managing symptoms, often with medications that carry long-term risks. A live biotherapeutic product based on S. hominis A9 could prevent flare-ups altogether, restoring microbial balance before inflammation begins. Beyond eczema, the findings may apply to other skin conditions linked to dysbiosis, such as psoriasis, acne, and even wound infections. Pharmaceutical companies are already exploring topical formulations, including creams and sprays that deliver live bacteria to the skin. Regulatory hurdles remain—live microbes are harder to standardize than chemical drugs—but the FDA has recently established pathways for microbiome-based therapies, signaling growing acceptance. If clinical trials confirm safety and efficacy, such treatments could become available within five to seven years, marking the first time a ‘probiotic’ is used to treat a chronic inflammatory skin disease.
\n
The Bigger Picture
\n
This research is part of a broader scientific awakening to the human microbiome’s role in health. Once dismissed as mere passengers, microbes are now recognized as active participants in immune regulation, metabolism, and disease prevention. The skin, long thought to be a mere barrier, is emerging as an immunological organ shaped by its microbial tenants. By leveraging these relationships, medicine may move from a model of eradication—killing all bacteria with antibiotics—to one of restoration, where health is maintained by nurturing beneficial alliances. The success of fecal microbiota transplants in treating C. difficile infections has already proven that microbial ecosystems can be therapeutically rebalanced. Now, the same principle may apply to the skin.
\n
What comes next is a new frontier in dermatology: personalized microbial therapies tailored to an individual’s skin ecology. Scientists are already mapping how microbial communities vary by age, geography, and genetics. The day may come when a child’s risk of eczema is assessed not just through family history, but through a swab of their skin microbiome—and when treatment begins not with a prescription, but with a vial of their own protective bacteria, amplified and returned. The future of medicine may not lie in synthetic compounds, but in the ancient, intimate partnerships between humans and the microbes that call us home.
Source: Manchester